Advertisement

Journal of Gastrointestinal Cancer

, Volume 49, Issue 1, pp 41–49 | Cite as

Pancreatic Cancer Management and Treatment Landscape Awareness of Gastroenterologists: Results from US Physician Surveys Conducted in 2013 and 2015

  • Gregory D SalinasEmail author
  • Lee Whitworth
  • Patti Merwin
  • Joan Emarine
Original Research

Abstract

Introduction

In the US, gastroenterologists (GIs) often inform patients of the initial diagnosis of pancreatic cancer. Thus, GIs are frequently the first physicians to provide vital information regarding treatment strategies and options to patients which can have significant impact on subsequent clinical decision-making. Since treatments for pancreatic cancer are rapidly evolving, it may be challenging for GIs to maintain an adequate knowledge base required to provide accurate cursory information or avoid providing inaccurate data to patients at a very sensitive point in time in their care. However, little to no published data are available on the treatment awareness, knowledge, and comfort of GIs in the United States who diagnose pancreatic cancer.

Methods

This study evaluated the self-reported management of pancreatic cancer, including patient discussion, familiarity with treatments, and use of guidelines. A survey was developed and fielded to US academic and community GIs in 2013. In 2015, the survey was redistributed as a follow-up to determine whether familiarity and practice has shifted; two questions were added, all other items remained identical. For the 2013 sample, 432 GIs were contacted and 113 valid responses were collected (26.2). For the 2015 sample, 712 GIs were contacted and 126 valid responses were collected (17.7%). Analysis compared differences between academic and community gastroenterologists and gastroenterologists performing endoscopic ultrasound (EUS) versus those that do not.

Results

Self-reported familiarity with pancreatic cancer therapies has not significantly increased from 2013 to 2015, as gastroenterologists report highest familiarity with 5-fluorouracil and gemcitabine. In the 2015 sample, 68% of academic and 58% of community gastroenterologists entered gemcitabine when identifying therapies FDA-approved for treatment of pancreatic cancer. However, 16% of academic and 24% of community gastroenterologists indicated that they were unaware of which therapies are approved, and some indicated therapies that are not FDA-approved for the treatment of pancreatic cancer, such as capecitabine (10%) and paclitaxel (7%). Gastroenterologists in 2015 are significantly more likely than in 2013 to discuss clinical trial enrollment with their patients with metastatic pancreatic cancer (5.5 on a 10-point scale vs 4.2, P = .013) but were not more confident in their ability to conduct such discussions. When managing patients with pancreatic cancer, academic, and community gastroenterologists responded that they were most likely to refer to guidelines developed by their professional organizations, such as the AGA and ACG. However, these groups have not developed specific guidelines for the management of patients with pancreatic cancer.

Conclusions

As gastroenterologists are frequently the first physicians to disclose a diagnosis of pancreatic cancer, education is needed to improve familiarity with current available treatments, clinical trials, and emerging therapies and resources to advise their patients.

Keywords

Pancreatic cancer Gastroenterologist Pancreatic cancer treatment Survey 

References

  1. 1.
    National Cancer Institute. SEER Stat Fact Sheets: Pancreas Cancer. Available at: http://seer.cancer.gov/statfacts/html/pancreas.html. Accessed on August 13, 2015.
  2. 2.
    Matrisian LM, Aizenberg R, Rosenzweig A. The alarming rise of pancreatic cancer deaths in the United States: why we need to stem the tide today. Available at: https://www.pancan.org/wp-content/uploads/2013/01/incidence_report_2012.pdf. Accessed on August 13, 2015.
  3. 3.
    Enweluzo C, Dutta S, Aziz F, Lenfest S. From acute pancreatitis to stage IV pancreatic cancer in 12 Weeks. Case Rep Gastroenterol. 2013 Jul 13;7(2):287–92.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Vincent A, Herman J, Schulick R, Hruban RH, Goggins M. Pancreatic cancer. Lancet. 2011 Aug 13;378(9791):607–20.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Engebretson A, Matrisian L, Thompson C. Pancreatic cancer: patient and caregiver perceptions on diagnosis, psychological impact, and importance of support. Pancreatology. 2015 Nov-Dec;15(6):701–7.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2016

Authors and Affiliations

  • Gregory D Salinas
    • 1
    Email author
  • Lee Whitworth
    • 1
  • Patti Merwin
    • 2
  • Joan Emarine
    • 2
  1. 1.CE Outcomes, LLCBirminghamUK
  2. 2.Department of Scientific EducationCelgene CorporationSummitUSA

Personalised recommendations